Prof Jennifer Woyach speaks to ecancer about a clinical trial evaluating the drug MS-553 (a selective PKCβ inhibitor) for patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

This study shows that MS-553 can be a promising agent in treating chronic lymphocytic leukaemia (CLL).

In this study researchers utilised genetically engineered CLL cells and mouse models to assess the drug's effectiveness.

She says that preliminary results from this phase one clinical trial indicate its potential, leading to plans for further clinical trials.